Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy

Table 3 Correlations between FACT/GOG-Ntx subscale scores and other measures’ scores at each assessment point

Scales	Ntx subscale^a
Scales	Baseline (n = 343)	Cycle 1 (n = 307)	Cycle 2 (n = 286)	Cycle 3 (n = 270)	Cycle 4 (n = 240)	Cycle 5 (n = 138)	Cycle 6 (n = 118)	6mFU (n = 254)	9mFU (n = 235)	12mFU (n = 195)
EORTC QLQ CIPN-20	0.852**	0.849**	0.891**	0.813**	0.890**	0.897**	0.902**	0.925**	0.925**	0.794**
NCI-CTCAE ³
Motor	0.145**	0.264**	0.301**	0.342**	0.391**	0.488**	0.496**	0.439**	0.435**	0.467**
Sensory	0.10	0.231**	0.340**	0.357**	0.370**	0.414**	0.376**	0.428**	0.446**	0.428**
Light touch using 10-g Monofilament	0.078	0.234**	0.249**	0.226**	0.257**	0.452**	0.280**	0.447**	0.473**	0.277**

Note: FACT/GOG-Ntx subscale = Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity subscale; EORTC QLQ-CIPN20 = European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Scale 20; NCI-CTCAE = National Cancer Institute -Common Terminology Criteria for Adverse Event; m=month; FU= follow-up
** p < 0.01
^aCalculated means for 0.3SD and 05 SD for the subscale at baseline and follow-up time points

ISSN: 1477-7525